Navigation Links
Genetic Disorder Drug Helps Reverse Heart Muscle Enlargement
Date:5/30/2008

Mice given BH4 had lower production of toxic free radicals from hypertension, study finds

FRIDAY, May 30 (HealthDay News) -- Tests on mice suggest that the drug BH4 may hold promise as a treatment for people with enlarged hearts, says a Johns Hopkins University study.

Currently, BH4 is used to treat a genetic disorder called phenylketonuria (PKU), a metabolic disorder in which a toxic buildup of a molecule called phenylalanine can cause brain damage.

In this study, the Hopkins team found that BH4 stabilized the pumping function of failing, enlarged hearts in mice and significantly decreased the size of the heart muscle in just over a month.

"Our results show for the first time the pivotal role played by BH4 in stopping and reversing the weakening and damage done -- even in severe cases -- to the heart muscle as a result of hypertension and subsequent hypertrophy [enlargement]," senior investigator Dr. David Kass, a professor at the Johns Hopkins University School of Medicine and its Heart Institute, said in a prepared statement.

"This key evidence may help us develop new therapies that stop and reverse hypertrophy, preventing the disease from leading to end-stage heart failure and keeping affected individuals from needing heart-assist pumps or a treatment of last resort, the heart transplant," Kass said.

In this study, the researchers gave a daily dose of 5 milligrams of BH4 per 25 grams of body weight to 31 mice whose hearts were damaged by hypertension. This group of mice was compared to a group of mice with hypertension-damaged hearts who received a placebo.

After five weeks, the BH4 group showed "remarkable improvements" compared to the placebo group. Ejection-fraction measures of heart pumping function improved from 48 percent at the start of BH4 treatment to 59 percent by the end of the study. In the placebo group, average pumping function decreased from 48 percent to 35 percent.

Heart weight, as measured by muscle mass, decreased from an average of 290 milligrams at the start of BH4 treatment to an average of 209 milligrams by the end of the study. In the placebo group, average heart weight was 330 milligrams by the end of the study.

The BH4 group also showed improvements in other areas, including heart wall thickness, muscle cell size and fibrosis, and lowered production of dangerous free radicals.

The study was published in the May 20 issue of Circulation.

More information

The American Heart Association has more about heart failure.



-- Robert Preidt



SOURCE: Johns Hopkins University, news release, May 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. USC researchers identify genetic markers that predict efficacy of novel cancer drug
2. Common Genetic Variant Tied to Lung Cancer Risk
3. Determining genetic signature of lung tumors can help guide treatment
4. Will lung cancer recur? A genetic test may provide the answer
5. Genetic loci assigned for musical aptitude in Finnish families
6. Geneticists at the American Museum of Natural History trace the evolution of St. Louis encephalitis
7. Genetic links to impaired social behavior in autism
8. Genetic Engineering and Biotechnology News reports on early ADMET use
9. Combined physical and genetic map finds cancers ignition key
10. Research program focuses on genetic mutations and cancer risk
11. Pelosi: Genetic Information Nondiscrimination Act Will Protect Americans from Misuse of Genetic Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce ... process has been in place since the RBMA was founded in 1968 with all ... Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... and College of Urgent Care Medicine will host industry leaders for the annual ... will help those in the industry adapt to the issues currently affecting urgent ...
(Date:4/28/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has ... which He does not. Yisrayl says with so many titles and names for the ... he says with a little Scripture, backed with a lot of research, the truth is ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... skincare and advanced nutraceutical supplements, through its Nova Skin Sciences division, recently ... hydrating benefits of a moisturizer with the power of an anti-aging concentrate. ...
(Date:4/28/2017)... ... 2017 , ... Christie Medical Holdings, Inc. , with its market-leading ... Medical Inc. , a leader in infusion therapy and pain management. , Intravenous ... percent of hospital patients receiving a peripheral IV catheter as part of their treatment ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , Tenn. and DALLAS , April 19, ... Inc., announced that the first patients in ... EndoStim device in the Lower Esophageal Sphincter Stimulation for ... minimally-invasive implantable device designed to provide long-term reflux control ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-na├»ve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology: